496 related articles for article (PubMed ID: 21719531)
21. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.
Magnussen H; Verkindre C; Jack D; Jadayel D; Henley M; Woessner R; Higgins M; Kramer B;
Respir Med; 2010 Dec; 104(12):1869-76. PubMed ID: 20850959
[TBL] [Abstract][Full Text] [Related]
22. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
Beeh KM; Beier J
Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
[TBL] [Abstract][Full Text] [Related]
23. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
Bauwens O; Ninane V; Van de Maele B; Firth R; Dong F; Owen R; Higgins M
Curr Med Res Opin; 2009 Feb; 25(2):463-70. PubMed ID: 19192991
[TBL] [Abstract][Full Text] [Related]
24. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
Rossi A; Centanni S; Cerveri I; Gulotta C; Foresi A; Cazzola M; Brusasco V
Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851
[TBL] [Abstract][Full Text] [Related]
25. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
Mahler DA; D'Urzo A; Bateman ED; Ozkan SA; White T; Peckitt C; Lassen C; Kramer B;
Thorax; 2012 Sep; 67(9):781-8. PubMed ID: 22544891
[TBL] [Abstract][Full Text] [Related]
26. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
Jones PW; Mahler DA; Gale R; Owen R; Kramer B
Respir Med; 2011 Jun; 105(6):892-9. PubMed ID: 21397482
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
Brookman LJ; Knowles LJ; Barbier M; Elharrar B; Fuhr R; Pascoe S
Curr Med Res Opin; 2007 Dec; 23(12):3113-22. PubMed ID: 17999782
[TBL] [Abstract][Full Text] [Related]
28. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.
Balint B; Watz H; Amos C; Owen R; Higgins M; Kramer B;
Int J Chron Obstruct Pulmon Dis; 2010 Sep; 5():311-8. PubMed ID: 20856830
[TBL] [Abstract][Full Text] [Related]
29. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
30. An update on the use of indacaterol in patients with COPD.
Brienza NS; Amor-Carro O; Ramos-Barbón D
Ther Adv Respir Dis; 2011 Feb; 5(1):29-40. PubMed ID: 21059700
[TBL] [Abstract][Full Text] [Related]
31. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.
Pearlman DS; Greos L; LaForce C; Orevillo CJ; Owen R; Higgins M
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):90-5. PubMed ID: 18681090
[TBL] [Abstract][Full Text] [Related]
32. Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.
Tashkin DP
Expert Opin Pharmacother; 2010 Aug; 11(12):2077-85. PubMed ID: 20642373
[TBL] [Abstract][Full Text] [Related]
33. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.
Beeh KM; Derom E; Kanniess F; Cameron R; Higgins M; van As A
Eur Respir J; 2007 May; 29(5):871-8. PubMed ID: 17251236
[TBL] [Abstract][Full Text] [Related]
34. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
[TBL] [Abstract][Full Text] [Related]
35. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
Wedzicha JA; Buhl R; Lawrence D; Young D
Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
[TBL] [Abstract][Full Text] [Related]
36. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
van Noord JA; Buhl R; Laforce C; Martin C; Jones F; Dolker M; Overend T
Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
[TBL] [Abstract][Full Text] [Related]
37. Indacaterol. A long-acting beta-2 agonist, no advantages in COPD.
Prescrire Int; 2011 Sep; 20(119):201-5. PubMed ID: 21954512
[TBL] [Abstract][Full Text] [Related]
38. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
39. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
Decramer M; Rossi A; Lawrence D; McBryan D
Respir Med; 2012 Dec; 106(12):1706-14. PubMed ID: 23031496
[TBL] [Abstract][Full Text] [Related]
40. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
Wang J; Nie B; Xiong W; Xu Y
J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
